Get Started on VPRIV
In order to begin treatment with VPRIV, you should work with your physician to complete, sign and submit a Start Form, available for download.
If you have questions about the form, please contact us
Terms and Conditions relating to the Use of Web Site
Shire Human Genetic Therapies, Inc. (“Shire HGT” or “we”) is pleased to provide you with this Website (the “Site”) and its content for general informational purposes. Please carefully read these Terms and Conditions relating to the use of the Site. Shire HGT will use reasonable efforts to ensure that the information is accurate at the time it is added to the Site. Please note, however, that Shire HGT makes no warranties or representations that the information is accurate and accepts no liability for any errors or omissions in the content of this Site or any losses or damage that may arise from relying on this information. By using this Site, you agree to these Terms and Conditions without limitation or qualification. If you do not agree to these Terms and Conditions, please do not use this Site.
Changes to Terms and Conditions
Shire HGT reserves the right to make additions, deletions and/or changes to the information and/or materials on the Site, including these Terms and Conditions, at any time without prior notification. You are bound by any such revisions and should, for this reason, periodically visit this page to review the current terms and conditions.
Use of Materials and Intellectual Property Rights
The copyright in this Site belongs to Shire HGT. All other intellectual property rights are reserved. Shire HGT authorizes you to copy materials published on this Site for non-commercial use only, provided that any copy of these materials which you make retains all copyright and other proprietary notices.
Links to Third Party Websites
This Site may contain links or references to other Websites. Please be aware that Shire HGT does not control other Websites and that Shire HGT’s Online Privacy Policy does not apply to those Websites. We encourage you to read the privacy policy of every Website you visit. We are not responsible for, nor do we endorse, the contents of these other Websites. If you in any way rely on information obtained from any such Websites, you do so at your own risk.
Information is No Substitute for Consulting a Health Professional
The information on this Site is intended only to provide knowledge of disease information. This information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other health care provider. Shire HGT does not recommend the self-management of health problems. Should you have any health care-related questions, please call or see your physician or other health care provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.
Information is not necessarily accurate, complete, or current
The information on the Website is intended only to provide knowledge of disease information. This information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other health care provider. Shire HGT does not recommend the self-management of health problems. Should you have any health care-related questions, please call or see your physician or other health care provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read on this Site.
Shire HGT is not responsible for computer damage resulting from using the Website
Information accessed on this Site is not exhaustive. Shire HGT makes reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations as to its accuracy or completeness. This information is provided “as is” without warranty of any kind, either express or implied, including but not limited to implied warranty of fitness for a particular purpose.
Shire HGT is not responsible for computer damage resulting from using this Site
Shire HGT makes no representation or warranty that access to this Site will be available on a timely basis, will be uninterrupted, or will be error-free. Shire HGT does not warrant that the pages of this Site, or the server that makes them available, are free of viruses or other harmful elements. In no event shall Shire HGT, its affiliates and subsidiaries, and their respective officers directors, employees, agents, representatives, information providers, and licensors and their respective heirs and assigns, be liable for any direct indirect, incidental, consequential, exemplary, special, punitive, or other damages even if informed of the possibility of such damages. The above exclusion may not apply in jurisdictions to the extent that they do not allow the exclusion of implied warranties.
Information
Any personally identifiable information in electronic communications to this Website is governed by Shire HGT’s Online Privacy Policy. Shire HGT shall be free to use or copy all other information in any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purposes, including disclosure to third parties and/or developing, manufacturing and/or marketing products or services.
Information intended for U.S. residents only
All materials and information appearing on this Site are intended for U.S. residents only and are intended to comply with the laws and regulations in the U.S. Other countries may have laws, regulations, regulatory requirements and medical practices that differ from those in the U.S. Shire HGT reserves the right to limit provision of Shire HGT’s products or services to any jurisdiction, geographic region or person. Any offer for any product or service made on this Site is void where prohibited.
These Terms and Conditions were last updated: August 16, 2011.
VPRIV is available by prescription only.
Indication
VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.
Important Safety Information
- The most serious side effects seen in patients in clinical trials with VPRIV were allergic reactions. Patients who have experienced allergic reactions to VPRIV or to other enzyme replacement therapy should proceed with caution.
- The most common side effects observed in clinical trials in patients treated with VPRIV were infusion-related and included: headache, dizziness, low blood pressure, high blood pressure, nausea, weakness/fatigue, and fever. Generally, infusion-related reactions were mild and, in newly treated patients, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.
- Management of infusion-related reactions is based on severity and may include slowing the infusion rate, treatment with medications such as antihistamines, fever-reducing agents and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. Side effects and any treatment concerns should be discussed with your physician.
- The most commonly reported side effects (occurring in ≥10% of patients) that were considered related to VPRIV included: headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, aPTT prolonged (eg, blood clotting difficulty), infusion-related reactions, fever, and weakness/fatigue.
- All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.
- As with all therapeutic proteins, there is the potential of developing antibodies. It is unknown if the presence of antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies.
- Your doctor may prescribe VPRIV to you if you are pregnant, only if it is clearly necessary.
- Tell your healthcare provider if you experience any side effects. For more information about VPRIV, ask your healthcare provider, read the Full Prescribing Information, visit www.VPRIV.com, or call Shire at 1-866-888-0660.
- You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
